Pharma News, 2025

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the poster pr...

Johnson & Johnson (JNJ) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD) for the treatmen...

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Incyte’s stock price has taken a hit of more than 11%, despite two Phase III trials investigating its oral small-molecule JAK1 inhibitor in hidradenitis suppurativa (HS) hitting their pr...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to $1.14bn, representing another big-dollar deal for the promising cancer ...

SAN DIEGO -- Cidara Therapeutics, Inc., a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced the publication ...

The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European Union.

Terpenes from the Cannabis sativa plant may be a viable medication for fibromyalgia and post-surgical pain relief, according to University of Arizona Health Sciences research published in Pharmacologi...

Mallinckrodt Pharmaceuticals and Endo have agreed to merge in a $6.7bn deal, combining two pharmaceutical companies that recently emerged from bankruptcy proceedings tied to opioid litigation.

SAN DIEGO---Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two...

The European Commission (EC) has approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic Rxulti (brexpiprazole) for schizophrenia in adolescents aged 13 years and a...

Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system atrophy (MSA).